Erin Duffy, PhD, is Chief of Research and Development at the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator, or CARB-X—a global partnership hosted at Boston University that is focused on supporting developers of promising new antibiotics, diagnostics, and vaccines that tackle the threat of untreatable bacterial infections. Dr. Duffy leads the growth and oversight of CARB-X’s portfolio of antibiotics, diagnostics, vaccines and other life-saving products addressing antibacterial resistance on a global level. She will present for our July 2021 Levy CIMAAR Science Lunch on the CARB-X portfolio as well as the science behind it. (More to come.)

Dr. Duffy joined CARB-X with 17+ years of drug-discovery experience in the antibiotic arena.  She joined then Rib-X Pharmaceuticals (now Melinta Therapeutics) as it was nucleating in New Haven, Connecticut, where in increasing roles she helped to build and sustain a team of researchers that translated the company’s scientific platform into next-generation and novel antibiotics that target the ribosome.  Her team’s most recent achievements include the de novo design and optimization of a completely new class of antibiotics, the pyrrolocytosines, which were supported in part by CARB-X.